1. Show article details.

    BRIEF-Johnson & Johnson Appoints Thibaut Mongon As CEO Designate Of Planned New Consumer Health Company

    Reuters – 6:32 AM ET 05/11/2022

    JOHNSON & JOHNSON - * JOHNSON & JOHNSON APPOINTS THIBAUT MONGON AS CEO DESIGNATE OF PLANNED NEW CONSUMER HEALTH COMPANY. * J&J - PLANNED SEPARATION OF CONSUMER HEALTH BUSINESS EXPECTED TO OCCUR WITHIN 2023. * J&J - APPOINTED PAUL RUH AS CFO DESIGNATE OF FUTURE, LISTED NEW CONSUMER HEALTH COMPANY.

  2. Show article details.

    J&J appoints consumer health head Thibaut Mongon to CEO of spun-off business

    Reuters – 6:30 AM ET 05/11/2022

    Johnson & Johnson (JNJ) on Wednesday appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of next year.

  3. Show article details.

    Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

    PR Newswire – 6:30 AM ET 05/11/2022

    The Company has also appointed Paul Ruh as CFO Designate Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business Planned Separation Expected to Occur in 2023 NEW BRUNSWICK, N.J., May 11, 2022 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh ...

  4. Show article details.

    Pharmacy chains should pay $878 mln for opioid epidemic role, Ohio counties say

    Reuters – 12:05 PM ET 05/10/2022

    A lawyer for two Ohio counties said on Monday that CVS Health Corp (CVS), Walgreens Boots Alliance Inc (WBA) and Walmart Inc (WMT) should fund an $878 million plan to address the opioid crisis there, as a first-of-its-kind trial got underway to determine the pharmacy chains' contribution.

  5. Show article details.

    What you need to know about the coronavirus right now

    Reuters – 8:40 AM ET 05/10/2022

    Here's what you need to know about the pandemic right now: Tesla stutters under tighter Shanghai lockdown; Beijing keeps hunting COVID. Tesla operated its Shanghai plant well below capacity on Tuesday, showing the problems factories face trying to ramp up output under a tightening COVID lockdown, while China's capital kept up its fight with a small but stubborn outbreak.

  6. Show article details.

    Walgreens, CVS, Walmart begin $878 million opioid trial in Ohio

    Reuters – 6:00 AM ET 05/10/2022

    CVS Health Corp (CVS), Walgreens Boots Alliance Inc (WBA) and Walmart Inc (WMT) on Tuesday begin a first-of-its-kind trial to determine what the pharmacy chains owe for their role in the opioid epidemic in two Ohio counties, which are seeking $878 million.

  7. Show article details.

    This Is What Whales Are Betting On Johnson & Johnson

    Benzinga – 4:43 PM ET 05/09/2022

    A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson we detected 20 strange trades. If we consider the specifics of each trade, it is accurate to state that 65% of the investors opened trades with bullish expectations and 35% with bearish.

  8. Show article details.

    WHO, Gavi not planning COVID vaccine buys from S.Africa's Aspen

    Reuters – 8:37 AM ET 05/09/2022

    * South Africa's Aspen facing poor demand for shots. * Could slash production without orders. * WHO, Gavi say supplies for COVAX initiative already secured. By Promit Mukherjee and Jennifer Rigby.

  9. Show article details.

    COVID vaccine makers shift focus to boosters

    Reuters – 6:00 AM ET 05/09/2022

    COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.

  10. Show article details.

    BRIEF-Janssen Discontinues Collaboration And License Agreements With Bavarian Nordic In Hepatitis B And Human Papillomavirus

    Reuters – 2:09 AM ET 05/09/2022

    Johnson & Johnson (JNJ): * JANSSEN DISCONTINUES COLLABORATION AND LICENSE AGREEMENTS WITH BAVARIAN NORDIC IN HEPATITIS B AND HUMAN PAPILLOMAVIRUS. * COLLABORATIONS BETWEEN JANSSEN AND BAVARIAN NORDIC IN HIV AND EBOLA CONTINUE. * NO CLINICAL STUDIES IN HEPATITIS B HAVE BEEN INITIATED BY JANSSEN UTILIZING MVA-BN TECHNOLOGY.

  11. Show article details.

    Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from variants

    Reuters – 1:42 PM ET 05/06/2022

    - The following is a summary of some recent studies on COVID-19. Obesity may weaken vaccine protection in the never infected. Severe obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study.

  12. Show article details.

    COVID SCIENCE-Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from variants

    Reuters – 1:13 PM ET 05/06/2022

    The following is a summary of some recent studies on COVID-19. Obesity may weaken vaccine protection in the never infected. Severe obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study.

  13. Show article details.

    The Daily Biotech Pulse: Limited Use Of JNJ's COVID-19 Shot, Myovant-Pfizer's Relugolix Application Delayed, Gain Therapeutics' Parkinson's Data

    Benzinga – 8:54 AM ET 05/06/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA said it was limiting the use of Johnson & Johnson's  COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome.

  14. Show article details.

    Cramer Gives His Opinion On CoreCivic, SGHC And More

    Benzinga – 8:50 AM ET 05/06/2022

    On CNBC's "Mad Money Lightning Round," Jim Cramer said Western Midstream Partners LP has a great yield. Cramer recommended staying away from CoreCivic, Inc.. When asked about Inmode Ltd, Cramer said, "If you want medtech, you just want Edwards Lifesciences Corporation ." The "Mad Money" host said SGHC Limited is "doing well, and I don't say that idly."

  15. Show article details.

    What you need to know about the coronavirus right now

    Reuters – 8:33 AM ET 05/06/2022

    Here's what you need to know about the pandemic right now: China hits back at 'zero COVID' doubters. Residents of Beijing fretted on Friday over dozens of new COVID-19 cases reported daily and over the possibility of more restrictions on movements as China's leaders threatened action against critics of their zero-COVID policy.

  16. Show article details.

    Morning Brief: Top Financial Stories Dominating on Friday, May 6

    Benzinga – 7:53 AM ET 05/06/2022

    Reuters IHG Hotels & Resorts On Way To Recovery As Travel Booms Tesla Battery Supplier CATL Said To Actively Explore Sites For US Manufacturing Plants US Regulators Reach China For Audit Deal Discussions Tesla Will Run Two Shifts At Shanghai Plant From May 16 Wall Street Journal Facebook Deliberately Caused Chaos In Attempt To Thwart Unfavorable Australian Law, Whistleblowers Allege Closely Wat...

  17. Show article details.

    FDA Limits Use of Johnson & Johnson's COVID-19 Vaccine to Certain Individuals - All You Should Know

    Benzinga – 7:23 AM ET 05/06/2022

    The FDA said it was limiting the use of Johnson & Johnson's  COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome. The J&J shot can be administered in cases where authorized or approved COVID-19 vaccines are not accessible, or if an individual is less keen on using the other two shots, the FDA said.

  18. Show article details.

    PRESS DIGEST- New York Times business news - May 6

    Reuters – 3:11 AM ET 05/06/2022

    The following are the top stories on the New York Times business pages. - U.S. President Joe Biden, Vice President Kamala Harris and Labor Secretary Martin J. Walsh met at the White House with several union organizers involved in successful campaigns at companies including Amazon (AMZN) and Starbucks (SBUX). nyti.ms/3KN4695.

  19. Show article details.

    PRESS DIGEST-Wall Street Journal - May 6

    Reuters – 2:11 AM ET 05/06/2022

    The following are the top stories in the Wall Street Journal. - Bausch + Lomb Corp priced its IPO at $18 a share, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market. https://on.wsj.com/3MRJw95.

  20. Show article details.

    U.S. limits use of J&J's COVID vaccine on blood clot risks

    Reuters – 8:01 PM ET 05/05/2022

    The U.S. health regulator said on Thursday it was limiting the use of Johnson & Johnson's COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome, the latest setback to the shot that has been eclipsed by rivals.

Page:

Today's and Upcoming Events

  • Jul
    19

    JNJ to announce Q2 earnings (Confirmed)

Past Events (last 90 days)

  • May
    23

    JNJ ex-Dividend for $1.13 on 05/23/2022

    • Announce Date: 04/19/2022
    • Record Date: 05/24/2022
    • Pay Date: 06/07/2022
  • Apr
    19

    JNJ announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.